Projets Majeurs et donateurs

The Laboratory of Excellence LipSTIC (for Lipoproteins and Health: Prevention and Treatment of Inflammatory Diseases and Cancer / LabEx, ANR-11-LABX-0021) focuses on lipoproteins as a vector for the transport of drugs or biologically active substances (fat-soluble vitamins, lipopolysacharides), or as a biological biomarker in chronic inflammatory pathologies (excluding atherosclerosis) and cancer. RIGHT coordinates the LabEX which includes 23 laboratories and 4 biotechs, including the spin-off MED’INN PHARMA.

RIGHT participates with the EFS Bourgogne Franche-Comté in the National Infrastructure in Biology and Health, E-Cell France (INBS, 11-INBS-0005), coordinated by the University of Montpellier, which aims to develop a national production platform for regenerative medicine based on mesenchymal stem cells

RIGHT participates in this SFRI, and more particularly, in the Graduate School (GS) dedicated to Health. One of the members of the unit, Professor Yann Godet, is deputy coordinator of the GS INTHERAPI.

Two areas of this GS overlap with the unit’s themes: cancer immunotherapy and targeted treatments in inflammatory diseases.

RIGHT is involved in the training of future researchers.

The European project « MiMédi » (

or “Microtechniques for Innovative Medicines”) aims to automate the production of biological medicines, such as advanced therapy medicines (or ITMs). UMR RIGHT coordinates the axis around the development of new biological drugs; it develops within this project these new biological drugs (CAR-T Cells, UCP-Vax vaccine, anti-inflammatory drugs based on the resolution of inflammation, HDL Therapy). UMR interacts within this project with the FEMTO-ST Institute, and 6 industrial partners from Franche-Comté, including its spin-off MED’INN PHARMA

The T2EVOLVE

consortium is the result of an alliance between European academic and industrial leaders in the field of cancer immunotherapy, and more particularly CAR-T cells. This consortium has been awarded the European Union’s H2020 Innovative Medicines Initiative (IMI) call for proposals. The main objective of T2EVOLVE is to accelerate the development of, and increase the awareness and access of cancer patients to immunotherapy with immune cells expressing a transgenic TCR or a CAR. In parallel, T2EVOLVE aims to provide guidance on the sustainable integration of these treatments into the EU healthcare system.

RIGHT is integrated in this consortium via INSERM which has 4 research units, 3 of which are located in the Paris area (Inserm US35 Evry [Anne Galy], Inserm U1223 Pasteur [Philippe Bousso], Inserm U1016 Cochin [Emmanuel Donnadieu, coordinator for INSERM]) and RIGHT [Christophe Ferrand, Philippe Saas]. The consortium is coordinated by Michael Hudecek from the University of Würzburg in Germany and Hélène Negre from Servier. It involves 27 partners, including 7 industrial partners (Astellas, Bayer, Celgene-BMS, Janssen, Milteniy Biotec, Servier and Takeda), a learned society (EHA), INCa, a patient association (European Cancer Patient Coalition) and prestigious research institutes (INSERM, Fraunhofer, Paul Ehrlich Institute) representing 10 EU countries (in addition to France, Germany, the Netherlands, Austria, Belgium, Switzerland, Italy, Spain, Luxembourg, and the United Kingdom)

Cette Fédération Hospitalo-Universitaire Integrated Center for REsearch in inflammatory diseASes (FHU InCREASe) s’intéresse aux maladies inflammatoires ainsi qu’aux maladies complexes avec une composante inflammatoire. Elle a pour objectif de développer la recherche, la formation et les soins dans ces pathologies. Elle est coordonnée par le professeur Didier Ducloux de l’UMR1098 RIGHT.

The Carnot Institutes aim to develop partnership research, i.e. partnerships between academic teams and industrial partners.

RIGHT participates in the Carnot Institute OPALE aiming to develop partnership research on leukemia. RIGHT participates through its research on the understanding of leukemias derived from plasmacytoid dendritic cells (or BPDCN, for blastic plasmacytoid dendritic cell neoplasm), or the pathophysiology of graft-versus-host disease (or GVH, a major complication of one of the treatments for leukemias, allogeneic transplantation of hematopoietic cells), and the development of CAR-T cells (IL-1RAP or CD123).

RIGHT is associated with the EFS Bourgogne Franche-Comté and the national EFS and the BioInnovation innovation center in the industrial integrator of the Grand Défi « BioProduction » which aims to develop and produce new biological drugs. The industrial integrators must support academic research teams, start-ups and companies in the development of their biologic drug projects or bioreactors for the production of these drugs. The aim is to support any innovation that can reduce the cost of producing biological drugs or increase their effectiveness. A transfer/maturation cell has been set up between RIGHT and the MTI activity of EFS Bourgogne Franche-Comté